Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 8/2011

01-05-2011 | Review Article

New Insights into the Pathogenesis and Treatment of Idiopathic Pulmonary Fibrosis

Authors: Qiang Ding, Tracy Luckhardt, Louise Hecker, Yong Zhou, Gang Liu, Veena B. Antony, Joao de Andrade, Dr Victor J. Thannickal

Published in: Drugs | Issue 8/2011

Login to get access

Abstract

Idiopathic pulmonary fibrosis (IPF) is the most common and lethal of the idiopathic interstitial pneumonias. There are currently no effective pharmacological therapies approved for the treatment of IPF. Despite the focus on targeting fibrogenic pathways, recent clinical trials have been largely disappointing. Progress is being made in elucidating key cellular processes and molecular pathways critical to IPF pathogenesis, and this should facilitate the development of more effective therapeutics for this recalcitrant disease. Emerging pathobiological concepts include the role of aging and cellular senescence, oxidative stress, endoplasmic reticulum stress, cellular plasticity, microRNAs and mechanotransduction. Therapeutic approaches that target molecular pathways to modulate aberrant cellular phenotypes and promote tissue homeostasis in the lung must be developed. Heterogeneity in biological and clinical phenotypes of IPF warrants a personalized medicine approach to diagnosis and treatment of this lung disorder.
Literature
1.
American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002; 165(2): 277–304
2.
Raghu G, Weycker D, Edelsberg J, et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006; 174(7): 810–6PubMedCrossRef
3.
Chailleux E, Fauroux B, Binet F, et al. Predictors of survival in patients receiving domiciliary oxygen therapy or mechanical ventilation: a 10-year analysis of ANTADIR Observatory. Chest 1996; 109(3): 741–9PubMedCrossRef
4.
Tzanakis N, Samiou M, Lambiri I, et al. Evaluation of health-related quality-of-life and dyspnea scales in patients with idiopathic pulmonary fibrosis: correlation with pulmonary function tests. Eur J Intern Med 2005; 16(2): 105–12PubMedCrossRef
5.
Harris-Eze AO, Sridhar G, Clemens RE, et al. Oxygen improves maximal exercise performance in interstitial lung disease. Am J Respir Crit Care Med 1994; 150 (6 Pt 1): 1616–22PubMed
6.
Madison JM, Irwin RS. Chronic cough in adults with interstitial lung disease. Curr Opin Pulm Med 2005; 11(5): 412–6PubMedCrossRef
7.
Tobin RW, Pope 2nd CE, Pellegrini CA, et al. Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 158(6): 1804–8PubMed
8.
Raghu G, Freudenberger TD, Yang S, et al. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J 2006; 27(1): 136–42PubMedCrossRef
9.
Raghu G, Yang ST, Spada C, et al. Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series. Chest 2006; 129(3): 794–800PubMedCrossRef
10.
Lancaster LH, Mason WR, Parnell JA, et al. Obstructive sleep apnea is common in idiopathic pulmonary fibrosis. Chest 2009; 136(3): 772–8PubMedCrossRef
11.
Hubbard RB, Smith C, Le Jeune I, et al. The association between idiopathic pulmonary fibrosis and vascular disease: a population-based study. Am J Respir Crit Care Med 2008; 178(12): 1257–61PubMedCrossRef
12.
Nathan SD, Basavaraj A, Reichner C, et al. Prevalence and impact of coronary artery disease in idiopathic pulmonary fibrosis. Respir Med 2010; 104(7): 1035–41PubMedCrossRef
13.
Lettieri CJ, Nathan SD, Barnett SD, et al. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006; 129(3): 746–52PubMedCrossRef
14.
Nadrous HF, Pellikka PA, Krowka MJ, et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest 2005; 128(4): 2393–9PubMedCrossRef
15.
American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161 (2 Pt 1): 646–64
16.
Raghu G, Brown KK, Bradford WZ, et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004; 350(2): 125–33PubMedCrossRef
17.
Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005; 171(9): 1040–7PubMedCrossRef
18.
Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353(21): 2229–42PubMedCrossRef
19.
Kubo H, Nakayama K, Yanai M, et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 2005; 128(3): 1475–82PubMedCrossRef
20.
King Jr TE, Behr J, Brown KK, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 177(1): 75–81PubMedCrossRef
21.
Raghu G, Brown KK, Costabel U, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med 2008; 178(9): 948–55PubMedCrossRef
22.
King Jr TE, Albera C, Bradford WZ, et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 2009; 374(9685): 222–8PubMedCrossRef
23.
Daniels CE, Lasky JA, Limper AH, et al. Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results. Am J Respir Crit Care Med 2010; 181(6): 604–10PubMedCrossRef
24.
Noble PW, Albera C, Bradford WZ, et al., for the CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. Epub 2011 May 13
25.
Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35(4): 821–9PubMedCrossRef
26.
Zisman DA, Schwarz M, Anstrom KJ, et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 2010; 363(7): 620–8PubMedCrossRef
27.
Martinez FJ, Safrin S, Weycker D, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005; 142 (12 Pt 1): 963–7PubMed
28.
National Heart, Lung, and Blood Institute (NHLBI). Anticoagulant effectiveness in idiopathic pulmonary fibrosis (ACE-IPF) [ClinicalTrials.gov identifier NCT00957242]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://​www.​clinicaltrials.​gov [Accessed 2011 May 25]
29.
InterMune. Three-arm study of the safety and efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis [ClinicalTrials.gov identifier NCT00287716]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://​www.​clinicaltrials.​gov [Accessed 2011 May 25]
30.
InterMune. Safety and efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis [ClinicalTrials.gov identifier NCT00287729]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://​www.​clinicaltrials.​gov [Accessed 2011 May 25]
31.
32.
Scott J, Johnston I, Britton J. What causes cryptogenic fibrosing alveolitis? A case-control study of environmental exposure to dust. BMJ 1990; 301(6759): 1015–7PubMedCrossRef
33.
Hubbard R, Lewis S, Richards K, et al. Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis. Lancet 1996; 347(8997): 284–9PubMedCrossRef
34.
Iwai K, Mori T, Yamada N, et al. Idiopathic pulmonary fibrosis: epidemiologic approaches to occupational exposure. Am J Respir Crit Care Med 1994; 150(3): 670–5PubMed
35.
Baumgartner KB, Samet JM, Coultas DB, et al. Occupational and environmental risk factors for idiopathic pulmonary fibrosis: a multicenter case-control study. Am J Epidemiol 2000; 152(4): 307–15PubMedCrossRef
36.
Miyake Y, Sasaki S, Yokoyama T, et al. Occupational and environmental factors and idiopathic pulmonary fibrosis in Japan. Ann Occup Hyg 2005; 49(3): 259–65PubMedCrossRef
37.
Pinheiro GA, Antao VC, Wood JM, et al. Occupational risks for idiopathic pulmonary fibrosis mortality in the United States. Int J Occup Environ Health 2008; 14(2): 117–23PubMed
38.
Gustafson T, Dahlman-Hoglund A, Nilsson K, et al. Occupational exposure and severe pulmonary fibrosis. Respir Med 2007; 101(10): 2207–12PubMedCrossRef
39.
Mullen J, Hodgson MJ, De Graff CA, et al. Case-control study of idiopathic pulmonary fibrosis and environmental exposures. J Occup Environ Med 1998; 40(4): 363–7PubMedCrossRef
40.
Kitamura H, Ichinose S, Hosoya T, et al. Inhalation of inorganic particles as a risk factor for idiopathic pulmonary fibrosis: elemental microanalysis of pulmonary lymph nodes obtained at autopsy cases. Pathol Res Pract 2007; 203(8): 575–85PubMedCrossRef
41.
Enomoto T, Usuki J, Azuma A, et al. Diabetes mellitus may increase risk for idiopathic pulmonary fibrosis. Chest 2003; 123(6): 2007–11PubMedCrossRef
42.
Steele MP, Speer MC, Loyd JE, et al. Clinical and pathologic features of familial interstitial pneumonia. Am J Respir Crit Care Med 2005; 172(9): 1146–52PubMedCrossRef
43.
Taskar VS, Coultas DB. Is idiopathic pulmonary fibrosis an environmental disease? Proc Am Thorac Soc 2006; 3(4): 293–8PubMedCrossRef
44.
Garcia-Sancho Figueroa MC, Carrillo G, Perez-Padilla R, et al. Risk factors for idiopathic pulmonary fibrosis in a Mexican population: a case-control study. Respir Med 2010; 104(2): 305–9PubMedCrossRef
45.
Antoniou KM, Hansell DM, Rubens MB, et al. Idiopathic pulmonary fibrosis: outcome in relation to smoking status. Am J Respir Crit Care Med 2008; 177(2): 190–4PubMedCrossRef
46.
King Jr TE, Tooze JA, Schwarz MI, et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001; 164(7): 1171–81PubMed
47.
Sweet MP, Patti MG, Leard LE, et al. Gastroesophageal reflux in patients with idiopathic pulmonary fibrosis referred for lung transplantation. J Thorac Cardiovasc Surg 2007; 133(4): 1078–84PubMedCrossRef
48.
Gribbin J, Hubbard R, Smith C. Role of diabetes mellitus and gastro-oesophageal reflux in the aetiology of idiopathic pulmonary fibrosis. Respir Med 2009; 103(6): 927–31PubMedCrossRef
49.
Savarino E, Bazzica M, Zentilin P, et al. Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring. Am J Respir Crit Care Med 2009; 179(5): 408–13PubMedCrossRef
50.
D’Ovidio F, Singer LG, Hadjiliadis D, et al. Prevalence of gastroesophageal reflux in end-stage lung disease candidates for lung transplant. Ann Thorac Surg 2005; 80(4): 1254–60PubMedCrossRef
51.
Fortunato GA, Machado MM, Andrade CF, et al. Prevalence of gastroesophageal reflux in lung transplant candidates with advanced lung disease. J Bras Pneumol 2008; 34(10): 772–8PubMedCrossRef
52.
Matsuse T, Ohga E, Teramoto S, et al. Immunohistochemical localisation of advanced glycation end products in pulmonary fibrosis. J Clin Pathol 1998; 51(7): 515–9PubMedCrossRef
53.
Chen L, Wang T, Wang X, et al. Blockade of advanced glycation end product formation attenuates bleomycin-induced pulmonary fibrosis in rats. Respir Res 2009; 10: 55PubMedCrossRef
54.
Englert JM, Hanford LE, Kaminski N, et al. A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosis. Am J Pathol 2008; 172(3): 583–91PubMedCrossRef
55.
Queisser MA, Kouri FM, Konigshoff M, et al. Loss of RAGE in pulmonary fibrosis: molecular relations to functional changes in pulmonary cell types. Am J Respir Cell Mol Biol 2008; 39(3): 337–45PubMedCrossRef
56.
Kelly BG, Lok SS, Hasleton PS, et al. A rearranged form of Epstein-Barr virus DNA is associated with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2002; 166(4): 510–3PubMedCrossRef
57.
Lok SS, Stewart JP, Kelly BG, et al. Epstein-Barr virus and wild p53 in idiopathic pulmonary fibrosis. Respir Med 2001; 95(10): 787–91PubMedCrossRef
58.
Stewart JP, Egan JJ, Ross AJ, et al. The detection of Epstein-Barr virus DNA in lung tissue from patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1999; 159 (4 Pt 1): 1336–41PubMed
59.
Tang YW, Johnson JE, Browning PJ, et al. Herpesvirus DNA is consistently detected in lungs of patients with idiopathic pulmonary fibrosis. J Clin Microbiol 2003; 41(6): 2633–40PubMedCrossRef
60.
Lawson WE, Crossno PF, Polosukhin VV, et al. Endoplasmic reticulum stress in alveolar epithelial cells is prominent in IPF: association with altered surfactant protein processing and herpesvirus infection. Am J Physiol Lung Cell Mol Physiol 2008; 294(6): L1119–26PubMedCrossRef
61.
Hayakawa H, Shirai M, Uchiyama H, et al. Lack of evidence for a role of Epstein-Barr virus in the increase of lung cancer in idiopathic pulmonary fibrosis. Respir Med 2003; 97(3): 281–4PubMedCrossRef
62.
Zamo A, Poletti V, Reghellin D, et al. HHV-8 and EBV are not commonly found in idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2005; 22(2): 123–8PubMed
63.
Mora AL, Woods CR, Garcia A, et al. Lung infection with gamma-herpesvirus induces progressive pulmonary fibrosis in Th2-biased mice. Am J Physiol Lung Cell Mol Physiol 2005; 289(5): L711–21PubMedCrossRef
64.
McMillan TR, Moore BB, Weinberg JB, et al. Exacerbation of established pulmonary fibrosis in a murine model by gammaherpesvirus. Am J Respir Crit Care Med 2008; 177(7): 771–80PubMedCrossRef
65.
Bitterman PB, Adelberg S, Crystal RG. Mechanisms of pulmonary fibrosis: spontaneous release of the alveolar macrophage-derived growth factor in the interstitial lung disorders. J Clin Invest 1983; 72(5): 1801–13PubMedCrossRef
66.
Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001; 134(2): 136–51PubMed
67.
Araki T, Katsura H, Sawabe M, et al. A clinical study of idiopathic pulmonary fibrosis based on autopsy studies in elderly patients. Intern Med 2003; 42(6): 483–9PubMedCrossRef
68.
Armanios M, Alder JK, Parry EM, et al. Short telomeres are sufficient to cause the degenerative defects associated with aging. Am J Hum Genet 2009; 85(6): 823–32PubMedCrossRef
69.
70.
Tsakiri KD, Cronkhite JT, Kuan PJ, et al. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci U S A 2007; 104(18): 7552–7PubMedCrossRef
71.
Alder JK, Chen JJ, Lancaster L, et al. Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc Natl Acad Sci U S A 2008; 105(35): 13051–6PubMedCrossRef
72.
Cronkhite JT, Xing C, Raghu G, et al. Telomere shortening in familial and sporadic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 178(7): 729–37PubMedCrossRef
73.
Thannickal VJ, Loyd JE. Idiopathic pulmonary fibrosis: a disorder of lung regeneration? Am J Respir Crit Care Med 2008; 178(7): 663–5PubMedCrossRef
74.
Matulionis DH. Chronic cigarette smoke inhalation and aging in mice: 1, morphologic and functional lung abnormalities. Exp Lung Res 1984; 7(3–4): 237–56PubMedCrossRef
75.
Kinnula VL, Fattman CL, Tan RJ, et al. Oxidative stress in pulmonary fibrosis: a possible role for redox modulatory therapy. Am J Respir Crit Care Med 2005; 172(4): 417–22PubMedCrossRef
76.
Brenner DA. Molecular pathogenesis of liver fibrosis. Trans Am Clin Climatol Assoc 2009; 120: 361–8PubMed
77.
Kuwano K, Kunitake R, Kawasaki M, et al. P21Waf1/Cip1/Sdi1 and p53 expression in association with DNA strand breaks in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1996; 154 (2 Pt 1): 477–83PubMed
78.
Montuschi P, Ciabattoni G, Paredi P, et al. 8-Isoprostane as a biomarker of oxidative stress in interstitial lung diseases. Am J Respir Crit Care Med 1998; 158 (5 Pt 1): 1524–7PubMed
79.
Kuwano K, Nakashima N, Inoshima I, et al. Oxidative stress in lung epithelial cells from patients with idiopathic interstitial pneumonias. Eur Respir J 2003; 21(2): 232–40PubMedCrossRef
80.
Lambeth JD. Nox enzymes, ROS, and chronic disease: an example of antagonistic pleiotropy. Free Radic Biol Med 2007; 43(3): 332–47PubMedCrossRef
81.
Dasari A, Bartholomew JN, Volonte D, et al. Oxidative stress induces premature senescence by stimulating caveolin-1 gene transcription through p38 mitogen-activated protein kinase/Sp1-mediated activation of two GC-rich promoter elements. Cancer Res 2006; 66(22): 10805–14PubMedCrossRef
82.
MacNee W. Accelerated lung aging: a novel pathogenic mechanism of chronic obstructive pulmonary disease (COPD). Biochem Soc Trans 2009; 37 (Pt 4): 819–23PubMedCrossRef
83.
Wang E. Senescent human fibroblasts resist programmed cell death, and failure to suppress bcl2 is involved. Cancer Res 1995; 55(11): 2284–92PubMed
84.
Campisi J, d’Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 2007; 8(9): 729–40PubMedCrossRef
85.
Toussaint O, Medrano EE, von Zglinicki T. Cellular and molecular mechanisms of stress-induced premature senescence (SIPS) of human diploid fibroblasts and melanocytes. Exp Gerontol 2000; 35(8): 927–45PubMedCrossRef
86.
Waghray M, Cui Z, Horowitz JC, et al. Hydrogen peroxide is a diffusible paracrine signal for the induction of epithelial cell death by activated myofibroblasts. FASEB J 2005; 19(7): 854–6PubMed
87.
Larios JM, Budhiraja R, Fanburg BL, et al. Oxidative protein cross-linking reactions involving L-tyrosine in transforming growth factor-beta1-stimulated fibroblasts. J Biol Chem 2001; 276(20): 17437–41PubMedCrossRef
88.
Xu C, Bailly-Maitre B, Reed JC. Endoplasmic reticulum stress: cell life and death decisions. J Clin Invest 2005; 115(10): 2656–64PubMedCrossRef
89.
Korfei M, Ruppert C, Mahavadi P, et al. Epithelial endoplasmic reticulum stress and apoptosis in sporadic idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 178(8): 838–46PubMedCrossRef
90.
Willis BC, Borok Z. TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease. Am J Physiol Lung Cell Mol Physiol 2007; 293(3): L525–34PubMedCrossRef
91.
Willis BC, Liebler JM, Luby-Phelps K, et al. Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta 1: potential role in idiopathic pulmonary fibrosis. Am J Pathol 2005; 166(5): 1321–32PubMedCrossRef
92.
Kim KK, Kugler MC, Wolters PJ, et al. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc Natl Acad Sci U S A 2006; 103(35): 13180–5PubMedCrossRef
93.
Tanjore H, Xu XC, Polosukhin VV, et al. Contribution of epithelial-derived fibroblasts to bleomycin-induced lung fibrosis. Am J Respir Crit Care Med 2009; 180(7): 657–65PubMedCrossRef
94.
Chilosi M, Poletti V, Zamo A, et al. Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis. Am J Pathol 2003; 162(5): 1495–502PubMedCrossRef
95.
Chilosi M, Zamo A, Doglioni C, et al. Migratory marker expression in fibroblast foci of idiopathic pulmonary fibrosis. Respir Res 2006; 7: 95PubMedCrossRef
96.
Hashimoto N, Phan SH, Imaizumi K, et al. Endothelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 2009; 43(2): 161–72PubMedCrossRef
97.
Burns AR, Smith CW, Walker DC. Unique structural features that influence neutrophil emigration into the lung. Physiol Rev 2003; 83(2): 309–36PubMed
98.
Sirianni FE, Milaninezhad A, Chu FS, et al. Alteration of fibroblast architecture and loss of Basal lamina apertures in human emphysematous lung. Am J Respir Crit Care Med 2006; 173(6): 632–8PubMedCrossRef
99.
Hinz B, Phan SH, Thannickal VJ, et al. The myofibroblast: one function, multiple origins. Am J Pathol 2007; 170(6): 1807–16PubMedCrossRef
100.
Hagood JS, Prabhakaran P, Kumbla P, et al. Loss of fibroblast Thy-1 expression correlates with lung fibrogenesis. Am J Pathol 2005; 167(2): 365–79PubMedCrossRef
101.
Zhou Y, Hagood JS, Murphy-Ullrich JE. Thy-1 expression regulates the ability of rat lung fibroblasts to activate transforming growth factor-beta in response to fibrogenic stimuli. Am J Pathol 2004; 165(2): 659–69PubMedCrossRef
102.
Rege TA, Hagood JS. Thy-1, a versatile modulator of signaling affecting cellular adhesion, proliferation, survival, and cytokine/growth factor responses. Biochim Biophys Acta 2006; 1763(10): 991–9PubMedCrossRef
103.
Zhou Y, Koli K, Hagood JS, et al. Latent transforming growth factor-beta-binding protein-4 regulates transforming growth factor-beta 1 bioavailability for activation by fibrogenic lung fibroblasts in response to bleomycin. Am J Pathol 2009; 174(1): 21–33PubMedCrossRef
104.
Bartel DP, Chen CZ. Micromanagers of gene expression: the potentially widespread influence of metazoan micro-RNAs. Nat Rev Genet 2004; 5(5): 396–400PubMedCrossRef
105.
van Rooij E, Sutherland LB, Thatcher JE, et al. Dysregulation of micro RNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U S A 2008; 105(35): 13027–32PubMedCrossRef
106.
Thum T, Gross C, Fiedler J, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008; 456(7224): 980–4PubMedCrossRef
107.
Pandit KV, Corcoran D, Yousef H, et al. Inhibition and role of let-7d in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2010; 182(2): 220–9PubMedCrossRef
108.
Liu G, Friggeri A, Yang Y, et al. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med 2010; 207(8): 1589–97PubMedCrossRef
109.
Kato M, Zhang J, Wang M, et al. MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci U S A 2007; 104(9): 3432–7PubMedCrossRef
110.
Shan H, Zhang Y, Lu Y, et al. Downregulation of miR-133 and miR-590 contributes to nicotine-induced atrial remodelling in canines. Cardiovasc Res 2009; 83(3): 465–72PubMedCrossRef
111.
Duisters RF, Tijsen AJ, Schroen B, et al. miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ Res 2009; 104(2): 170–8, 6p following 178PubMedCrossRef
112.
Cushing L, Kuang PP, Qian J, et al. MIR-29 is a major regulator of genes associated with pulmonary fibrosis. Am J Respir Cell Mol Biol. Epub 2010 Oct 22
113.
Sheedy FJ, Palsson-McDermott E, Hennessy EJ, et al. Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat Immunol 2010; 11(2): 141–7PubMedCrossRef
114.
Cheng Y, Zhu P, Yang J, et al. Ischaemic preconditioning-regulated miR-21 protects heart against ischaemia/reperfusion injury via anti-apoptosis through its target PDCD4. Cardiovasc Res 2010; 87(3): 431–9PubMedCrossRef
115.
Hatley ME, Patrick DM, Garcia MR, et al. Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell 2010; 18(3): 282–93PubMedCrossRef
116.
Roy S, Khanna S, Hussain SR, et al. MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc Res 2009; 82(1): 21–9PubMedCrossRef
117.
Kato M, Putta S, Wang M, et al. TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat Cell Biol 2009; 11(7): 881–9PubMedCrossRef
118.
Shan SW, Lee DY, Deng Z, et al. MicroRNA MiR-17 retards tissue growth and represses fibronectin expression. Nat Cell Biol 2009; 11(8): 1031–8PubMedCrossRef
119.
Cordes KR, Sheehy NT, White MP, et al. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature 2009; 460(7256): 705–10PubMed
120.
Pottier N, Maurin T, Chevalier B, et al. Identification of keratinocyte growth factor as a target of microRNA-155 in lung fibroblasts: implication in epithelial-mesenchymal interactions. PLoS One 2009; 4(8): e6718PubMedCrossRef
121.
Martin MM, Lee EJ, Buckenberger JA, et al. MicroRNA-155 regulates human angiotensin II type 1 receptor expression in fibroblasts. J Biol Chem 2006; 281(27): 18277–84PubMedCrossRef
122.
Gregory PA, Bert AG, Paterson EL, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008; 10(5): 593–601PubMedCrossRef
123.
Park SM, Gaur AB, Lengyel E, et al. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008; 22(7): 894–907PubMedCrossRef
124.
Korpal M, Lee ES, Hu G, et al. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008; 283(22): 14910–4PubMedCrossRef
125.
126.
Wipff PJ, Rifkin DB, Meister JJ, et al. Myofibroblast contraction activates latent TGF-beta 1 from the extracellular matrix. J Cell Biol 2007; 179(6): 1311–23PubMedCrossRef
127.
Dubois CM, Laprise MH, Blanchette F, et al. Processing of transforming growth factor beta 1 precursor by human furin convertase. J Biol Chem 1995; 270(18): 10618–24PubMedCrossRef
128.
Lawrence DA, Pircher R, Kryceve-Martinerie C, et al. Normal embryo fibroblasts release transforming growth factors in a latent form. J Cell Physiol 1984; 121(1): 184–8PubMedCrossRef
129.
Lawrence DA, Pircher R, Jullien P. Conversion of a high molecular weight latent beta-TGF from chicken embryo fibroblasts into a low molecular weight active beta-TGF under acidic conditions. Biochem Biophys Res Commun 1985; 133(3): 1026–34PubMedCrossRef
130.
Koli K, Saharinen J, Karkkainen M, et al. Novel non-TGF-beta-binding splice variant of LTBP-4 in human cells and tissues provides means to decrease TGF-beta deposition. J Cell Sci 2001; 114 (Pt 15): 2869–78PubMed
131.
Annes JP, Munger JS, Rifkin DB. Making sense of latent TGFbeta activation. J Cell Sci 2003; 116 (Pt 2): 217–24PubMedCrossRef
132.
Hyytiainen M, Penttinen C, Keski-Oja J. Latent TGF-beta binding proteins: extracellular matrix association and roles in TGF-beta activation. Crit Rev Clin Lab Sci 2004; 41(3): 233–64PubMedCrossRef
133.
Koli K, Wempe F, Sterner-Kock A, et al. Disruption of LTBP-4 function reduces TGF-beta activation and enhances BMP-4 signaling in the lung. J Cell Biol 2004; 167(1): 123–33PubMedCrossRef
134.
Munger JS, Huang X, Kawakatsu H, et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 1999; 96(3): 319–28PubMedCrossRef
135.
Sime PJ, Xing Z, Graham FL, et al. Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. J Clin Invest 1997; 100(4): 768–76PubMedCrossRef
136.
Yehualaeshet T, O’Connor R, Green-Johnson J, et al. Activation of rat alveolar macrophage-derived latent transforming growth factor beta-1 by plasmin requires interaction with thrombospondin-1 and its cell surface receptor, CD36. Am JPathol 1999; 155(3): 841–51CrossRef
137.
Gauldie J, Bonniaud P, Sime P, et al. TGF-beta, Smad3 and the process of progressive fibrosis. Biochem Soc Trans 2007; 35 (Pt 4): 661–4PubMedCrossRef
138.
Khalil N, O’Connor RN, Unruh HW, et al. Increased production and immunohistochemical localization of transforming growth factor-beta in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 1991; 5(2): 155–62PubMed
139.
Pohlers D, Brenmoehl J, Loffler I, et al. TGF-beta and fibrosis in different organs: molecular pathway imprints. Biochim Biophys Acta 2009; 1792(8): 746–56PubMedCrossRef
140.
Roberts AB, Tian F, Byfield SD, et al. Smad3 is key to TGF-beta-mediated epithelial-to-mesenchymal transition, fibrosis, tumor suppression and metastasis. Cytokine Growth Factor Rev 2006; 17(1–2): 19–27PubMedCrossRef
141.
Ahamed J, Burg N, Yoshinaga K, et al. In vitro and in vivo evidence for shear-induced activation of latent transforming growth factor-beta 1. Blood 2008; 112(9): 3650–60PubMedCrossRef
142.
Ahamed J, Janczak CA, Wittkowski KM, et al. In vitro and in vivo evidence that thrombospondin-1 (TSP-1) contributes to stirring- and shear-dependent activation of platelet-derived TGF-beta1. PLoS One 2009; 4(8): e6608PubMedCrossRef
143.
Saharinen J, Taipale J, Keski-Oja J. Association of the small latent transforming growth factor-beta with an eight cysteine repeat of its binding protein LTBP-1. EMBO J 1996; 15(2): 245–53PubMed
144.
Unsold C, Hyytiainen M, Bruckner-Tuderman L, et al. Latent TGF-beta binding protein LTBP-1 contains three potential extracellular matrix interacting domains. J Cell Sci 2001; 114 (Pt 1): 187–97PubMed
145.
Isogai Z, Ono RN, Ushiro S, et al. Latent transforming growth factor beta-binding protein 1 interacts with fibrillin and is a microfibril-associated protein. J Biol Chem 2003; 278(4): 2750–7PubMedCrossRef
146.
Jenkins RG, Su X, Su G, et al. Ligation of protease-activated receptor 1 enhances alpha(v)beta6 integrin-dependent TGF-beta activation and promotes acute lung injury. J Clin Invest 2006; 116(6): 1606–14PubMedCrossRef
147.
Sheppard D. Integrin-mediated activation of latent transforming growth factor beta. Cancer Metastasis Rev 2005; 24(3): 395–402PubMedCrossRef
148.
Zhou Y, Hagood JS, Lu B, et al. Thy-1-integrin alpha v beta5 interactions inhibit lung fibroblast contraction-induced latent transforming growth factor-beta1 activation and myofibroblast differentiation. J Biol Chem 2010; 285(29): 22382–93PubMedCrossRef
149.
Parsons JT, Slack-Davis J, Tilghman R, et al. Focal adhesion kinase: targeting adhesion signaling pathways for therapeutic intervention. Clin Cancer Res 2008; 14(3): 627–32PubMedCrossRef
150.
Thannickal VJ, Lee DY, White ES, et al. Myofibroblast differentiation by transforming growth factor-beta1 is dependent on cell adhesion and integrin signaling via focal adhesion kinase. J Biol Chem 2003; 278(14): 12384–9PubMedCrossRef
151.
Ding Q, Gladson CL, Wu H, et al. Focal adhesion kinase (FAK)-related non-kinase inhibits myofibroblast differentiation through differential MAPK activation in a FAK-dependent manner. J Biol Chem 2008; 283(40): 26839–49PubMedCrossRef
152.
Cai GQ, Zheng A, Tang Q, et al. Downregulation of FAK-related non-kinase mediates the migratory phenotype of human fibrotic lung fibroblasts. Exp Cell Res 2010; 316(9): 1600–9PubMedCrossRef
153.
Horowitz JC, Rogers DS, Sharma V, et al. Combinatorial activation of FAK and AKT by transforming growth factor-beta1 confers an anoikis-resistant phenotype to myofibroblasts. Cell Signal 2007; 19(4): 761–71PubMedCrossRef
154.
155.
Skhirtladze C, Distler O, Dees C, et al. Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis. Arthritis Rheum 2008; 58(5): 1475–84PubMedCrossRef
156.
Garneau-Tsodikova S, Thannickal VJ. Protein kinase inhibitors in the treatment of pulmonary fibrosis. Curr Med Chem 2008; 15(25): 2632–40PubMedCrossRef
157.
Kutz SM, Hordines J, McKeown-Longo PJ, et al. TGF-beta1-induced PAI-1 gene expression requires MEK activity and cell-to-substrate adhesion. J Cell Sci 2001; 114 (Pt 21): 3905–14PubMed
158.
Mulder KM. Role of Ras and Mapks in TGFbeta signaling. Cytokine Growth Factor Rev 2000; 11(1–2): 23–35PubMedCrossRef
159.
Roelen BA, Cohen OS, Raychowdhury MK, et al. Phosphorylation of threonine 276 in Smad4 is involved in transforming growth factor-beta-induced nuclear accumulation. Am J Physiol Cell Physiol 2003; 285(4): C823–30PubMed
160.
Furukawa F, Matsuzaki K, Mori S, et al. p38 MAPK mediates fibrogenic signal through Smad3 phosphorylation in rat myofibroblasts. Hepatology 2003; 38(4): 879–89PubMed
161.
Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010; 327(5962): 198–201PubMedCrossRef
162.
Ponomarev ED, Veremeyko T, Barteneva N, et al. Micro-RNA-124 promotes microglia quiescence and suppresses EAE by deactivating macrophages via the C/EBP-alpha-PU.1 pathway. Nat Med 2010; 17(1): 64–70PubMedCrossRef
163.
Cheng Y, Liu X, Yang J, et al. MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation. Circ Res 2009; 105(2): 158–66PubMedCrossRef
164.
Tomasek JJ, Gabbiani G, Hinz B, et al. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 2002; 3(5): 349–63PubMedCrossRef
165.
Kimura K, Ito M, Amano M, et al. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rhokinase). Science 1996; 273(5272): 245–8PubMedCrossRef
166.
Kawano Y, Fukata Y, Oshiro N, et al. Phosphorylation of myosin-binding subunit (MBS) of myosin phosphatase by Rho-kinase in vivo. J Cell Biol 1999; 147(5): 1023–38PubMedCrossRef
167.
Nishikimi T, Matsuoka H. Molecular mechanisms and therapeutic strategies of chronic renal injury: renoprotective effect of rho-kinase inhibitor in hypertensive glomerulosclerosis. J Pharmacol Sci 2006; 100(1): 22–8PubMedCrossRef
168.
169.
Oka M, Fagan KA, Jones PL, et al. Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension. Br J Pharmacol 2008; 155(4): 444–54PubMedCrossRef
170.
Schaafsma D, Gosens R, Zaagsma J, et al. Rho kinase inhibitors: a novel therapeutical intervention in asthma? Eur J Pharmacol 2008; 585(2–3): 398–406PubMedCrossRef
171.
Nagatoya K, Moriyama T, Kawada N, et al. Y-27632 prevents tubulointerstitial fibrosis in mouse kidneys with unilateral ureteral obstruction. Kidney Int 2002; 61(5): 1684–95PubMedCrossRef
172.
Murata T, Arii S, Nakamura T, et al. Inhibitory effect of Y-27632, a ROCK inhibitor, on progression of rat liver fibrosis in association with inactivation of hepatic stellate cells. J Hepatol 2001; 35(4): 474–81PubMedCrossRef
173.
Nishikimi T, Akimoto K, Wang X, et al. Fasudil, a Rhokinase inhibitor, attenuates glomerulosclerosis in Dahl salt-sensitive rats. J Hypertens 2004; 22(9): 1787–96PubMedCrossRef
174.
Boerma M, Fu Q, Wang J, et al. Comparative gene expression profiling in three primary human cell lines after treatment with a novel inhibitor of Rho kinase or atorvastatin. Blood Coagul Fibrinolysis 2008; 19(7): 709–18PubMedCrossRef
175.
Hinz B, Dugina V, Ballestrem C, et al. Alpha-smooth muscle actin is crucial for focal adhesion maturation in myofibroblasts. Mol Biol Cell 2003; 14(6): 2508–19PubMedCrossRef
176.
Hinz B, Gabbiani G, Chaponnier C. The NH2-terminal peptide of alpha-smooth muscle actin inhibits force generation by the myofibroblast in vitro and in vivo. J Cell Biol 2002; 157(4): 657–63PubMedCrossRef
177.
Cantin AM, North SL, Fells GA, et al. Oxidant-mediated epithelial cell injury in idiopathic pulmonary fibrosis. J Clin Invest 1987; 79(6): 1665–73PubMedCrossRef
178.
Cantin AM, Hubbard RC, Crystal RG. Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis. Am Rev Respir Dis 1989; 139(2): 370–2PubMedCrossRef
179.
National Heart, Lung, and Blood Institute (NHLBI). Evaluating the effectiveness of prednisone, azathioprine, and N-acetylcysteine in people with idiopathic pulmonary fibrosis (PANTHER-IPF) [ClinicalTrials.gov identifier NCT00650091]. US National Institutes of Health, Clinical Trials.gov [online]. Available from URL: http://​www.​clinicaltrials.​gov [Accessed 2011 May 25]
180.
Hecker L, Vittal R, Jones T, et al. NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat Med 2009; 15(9): 1077–81PubMedCrossRef
181.
Abrahams E, Silver M. The case for personalized medicine. J Diabetes Sci Technol 2009; 3(4): 680–4PubMed
182.
Aquino-Galvez A, Perez-Rodriguez M, Camarena A, et al. MICA polymorphisms and decreased expression of the MICA receptor NKG2D contribute to idiopathic pulmonary fibrosis susceptibility. Hum Genet 2009; 125(5–6): 639–48PubMedCrossRef
183.
Checa M, Ruiz V, Montano M, et al. MMP-1 polymorphisms and the risk of idiopathic pulmonary fibrosis. Hum Genet 2008; 124(5): 465–72PubMedCrossRef
184.
Rosas IO, Richards TJ, Konishi K, et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med 2008; 5(4): e93PubMedCrossRef
185.
Daniil ZD, Papageorgiou E, Koutsokera A, et al. Serum levels of oxidative stress as a marker of disease severity in idiopathic pulmonary fibrosis. Pulm Pharmacol Ther 2008; 21(1): 26–31PubMedCrossRef
186.
Kinder BW, Brown KK, McCormack FX, et al. Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest 2009; 135(6): 1557–63PubMedCrossRef
187.
Prasse A, Probst C, Bargagli E, et al. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179(8): 717–23PubMedCrossRef
188.
Xaubet A, Marin-Arguedas A, Lario S, et al. Transforming growth factor-beta 1 gene polymorphisms are associated with disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003; 168(4): 431–35PubMedCrossRef
Metadata
Title
New Insights into the Pathogenesis and Treatment of Idiopathic Pulmonary Fibrosis
Authors
Qiang Ding
Tracy Luckhardt
Louise Hecker
Yong Zhou
Gang Liu
Veena B. Antony
Joao de Andrade
Dr Victor J. Thannickal
Publication date
01-05-2011
Publisher
Springer International Publishing
Published in
Drugs / Issue 8/2011
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/11591490-000000000-00000

Other articles of this Issue 8/2011

Drugs 8/2011 Go to the issue

Adis Drug Profile

Denosumab

Leading Article

Molecular Targeted Therapy in Ovarian Cancer

Therapy in Practice

Efficacy and Safety of Long-Acting Reversible Contraception

Review Article

End-Organ Protection in Patients with Hypertension

R&D Insight Profile

Ipilimumab

Review Article

Pharmacotherapeutic Management of Locally Advanced Prostate Cancer